AdvaMed Q3 2025: Standing Firm for Medtech Amid Political Uncertainty
The third quarter of 2025 brought one of the most turbulent policy landscapes Washington has seen in years. Yet through it all, AdvaMed continued to deliver results—anchored by a commitment to bipartisan advocacy for the value of medical technology. From mobilizing rapid action in response to the U.S. Department of Commerce’s Section 232 investigation on medical device imports to advancing Medicare coverage for FDA-authorized breakthrough technologies, AdvaMed’s message remained clear: medtech saves and improves lives.
This quarter also marked strong progress in FDA user fee negotiations and positive signals from U.S.-EU trade discussions that could lower tariffs for critical medtech sectors. These achievements underscore a single truth—AdvaMed’s strength lies in its members.
Explore the full Q3 2025 report and join us in shaping the future of medtech policy.